Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Lencz, T. Articles by Malhotra, A. K. Search for Related Content PubMed Citation Articles by Lencz, T. Articles by Malhotra, A. K. Atypical Neuroleptics Schizophrenia Spectrum Disorders Genetics

DRD2 Promoter Region Variation as a Predictor of Sustained Response to Antipsychotic Medication in First-Episode Schizophrenia Patients

OBJECTIVE: All antipsychotics act on the dopamine D₂ receptor. The present study extends prior pharmacogenetic investigations of the D₂ receptor gene (DRD2) by examining, in first-episode schizophrenia patients, promoter region variation as a predictor of response time to two first-line atypical antipsychotics. METHOD: Patients experiencing their first episode of schizophrenia (N=61) were genotyped for two DRD2 promoter region polymorphisms (A-241G and –141C Ins/Del) and were randomly assigned to receive 16 weeks of treatment with either risperidone or olanzapine. Time until sustained response (two consecutive ratings without significant positive symptoms) for rare allele carriers versus wild types was examined by using Kaplan-Meier curves. RESULTS: Relative to wild type homozygotes, G carriers (A–241G) exhibited a significantly faster time until response, whereas –141C Del carriers took a significantly longer time to respond. Diplotype analysis revealed similar results. CONCLUSIONS: These findings suggest that variation in the D₂ receptor gene can, in part, explain variation in the timing of clinical response to antipsychotics in patients with first-episode schizophrenia.

This article has been cited by other articles:

				Y. Liu, C. Huang, P. Wu, Y. Chang, C. Huang, and H. Lane Lack of association between AKT1 variances versus clinical manifestations and social function in patients with schizophrenia J Psychopharmacol, November 1, 2009; 23(8): 937 - 943. [Abstract] [PDF]

				T. Lencz, R. H. Lipsky, P. DeRosse, K. E. Burdick, D. Goldman, C. Hodgkinson, J. M. Kane, and A. K. Malhotra Authors' reply The British Journal of Psychiatry, August 1, 2009; 195(2): 179 - 180. [Full Text] [PDF]

				M. J. Arranz and S. Kapur Pharmacogenetics in Psychiatry: Are We Ready for Widespread Clinical Use? Schizophr Bull, November 1, 2008; 34(6): 1130 - 1144. [Abstract] [Full Text] [PDF]

				S. G. Leckband, J. R. Bishop, and V. L. Ellingrod Pharmacogenomics in Psychiatry Journal of Pharmacy Practice, June 1, 2007; 20(3): 252 - 264. [Abstract] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2006 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us